Latest market price
54.49
-4.56-7.72%
OverviewShort InterestFilings
HTFLQT65Heartflow, Inc. Common Stock·NASDAQ
54.49-7.72%
News
Down 7.7% — AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry (globenewswire.com).
Medium confidence
TA
Loading chart...
Screen all →
WAY+0.50%$28.14DOCS+0.34%$32.87PRVA-0.93%$21.28HQY+1.17%$103.67HNGE+1.01%$115.48BTSG-0.94%$66.26OMCL-0.65%$36.41CERT-2.81%$10.71
Snapshot
Index—P/E—EPS (ttm)-1.42Insider Own30.28%Shs Outstand86.95MPerf Week-4.42%
Market Cap4.74BForward P/E—EPS next Y-0.27Insider Trans-1.72%Shs Float67.25MPerf Month10.48%
Enterprise Value4.60BPEG—EPS next Q-0.10Short Float10.90%Perf Quarter99.74%
Income-118.00MP/S22.35EPS this Y—Short Ratio3.99Perf Half Y88.22%
Sales212.00MP/B16.92EPS next Y—ROA-34.36%Short Interest7.33MPerf YTD86.93%
Book/sh3.22P/C29.07EPS next 5Y—ROE-42.25%52W High60.56 -10.02%Perf Year49.00%
Cash/sh1.87P/FCF—EPS past 3/5Y—ROIC-23.67%52W Low20.13 170.69%Perf 3Y—
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin80.08%Volatility6.18% 5.97%Perf 5Y—
Dividend TTM—EV/Sales21.71EPS Y/Y TTM—Oper. Margin-34.31%ATR (14)3.09Perf 10Y—
Dividend Ex-Date—Quick Ratio5.08Sales Y/Y TTM43.24%Profit Margin-55.82%RSI (14)53.03Recom2.17
Dividend Gr. 3/5Y—Current Ratio5.08EPS Q/Q-16.67%SMA201.90%Beta1.86Target Price48.86
Payout0.00%Debt/Eq0.10Sales Q/Q48.84%SMA507.02%Rel Volume0.84Prev Close59.05
Employees843LT Debt/Eq0.07EarningsNov 12SMA20059.29%Avg Volume1.95MPrice54.49
IPO DateAug 07, 2025Option/ShortYes / YesEPS/Sales Surpr.47.64% 13.15%Net Debt/EBITDA—Volume1,647,405Change-7.72%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-20-26ReiteratedPiper SandlerOverweight$45 → $64
Sep-22-26ReiteratedCanaccord GenuityBuy$45 → $56
Sep-09-26InitiatedUBSNeutral$55
Aug-14-26ReiteratedStifel Nicolaus$40 → $45
Aug-14-26ReiteratedRobert W. Baird$34 → $45
Aug-14-26ReiteratedCanaccord GenuityBuy$37 → $45
Aug-14-26ReiteratedMorgan StanleyEqual Weight$35 → $40
Aug-14-26ReiteratedPiper SandlerOverweight$38 → $45
Jul-31-26InitiatedBairdOutperform$34
Jul-15-26ReiteratedStifel Nicolaus$35 → $40
Latest News· Times ET
Nov-02-26
Nov-02-2608:00AM
AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registryglobenewswire.com
Nov-01-26
Nov-01-2601:45PM
TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patientsglobenewswire.com
Oct-28-26
Oct-28-2606:30AM
Boston Scientific announces results for third quarter 2026prnewswire.com
Oct-27-26
Oct-27-2605:20PM
Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue EstimatesYahoo
04:13AM
Heartflow (NASDAQ:HTFL) Insider Campbell Rogers Sells 23,933 Shares of Stockdefenseworld.net
Oct-20-26
Oct-20-2605:00AM
Piper Sandler Reiterates Overweight on HeartFlow, Raises Price Target to $64Benzinga
Oct-19-26
Oct-19-2604:01PM
Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026globenewswire.com
Oct-13-26
Oct-13-2609:35AM
10 Health Care Stocks With Whale Alerts In Today’s SessionBenzinga
Oct-10-26
Oct-10-2602:14PM
Pfizer And 2 Other Top AI Healthcare StocksYahoo
Oct-07-26
Oct-07-2608:21AM
Heartflow (NASDAQ:HTFL) Sets New 12-Month High – Should You Buy?defenseworld.net
Sep-29-26
Sep-29-2611:24AM
AI Cardiac Diagnostics Pioneer Sets HeartFlow (HTFL) for High-Margin ExpansionYahoo
Sep-22-26
Sep-22-2604:04AM
Canaccord Genuity Maintains Buy on HeartFlow, Raises Price Target to $56Benzinga
Sep-20-26
Sep-20-2605:56AM
Vikram Verghese Sells 7,579 Shares of Heartflow (NASDAQ:HTFL) Stockdefenseworld.net
05:10AM
Heartflow (NASDAQ:HTFL) Reaches New 52-Week High – Still a Buy?defenseworld.net
Sep-18-26
Sep-18-2603:15AM
12,278 Shares in Heartflow, Inc. $HTFL Bought by Amundidefenseworld.net
Company

HeartFlow, Inc. operates as a global medical technology firm, specializing in providing non-surgical solutions for the diagnosis and ongoing management of coronary artery disease. Its innovative HeartFlow Platform employs artificial intelligence and advanced computational fluid dynamics to generate a unique, three-dimensional digital replica of a patient's heart. This intricate model is created from a single coronary computed tomography angiography (CCTA), which is a specialized scan designed to produce highly detailed images of the heart's arterial network. The platform offers vital insights into aspects like blood flow, the extent of arterial narrowing (stenosis), and the volume and composition of any plaque present, thereby overcoming the limitations typically associated with traditional non-invasive imaging techniques. Founded in 2007, the company is headquartered in Mountain View, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
Total Revenue21217612687
Cost of Goods Sold Incl. D&A42413129
Gross Profit1691359458
Selling, General and Administrative Excl. Other15913411295
Research and Development84654436
Other Operating Expense
0000
Operating Income-73-64-61-73
Interest Expense3152325
Unusual Expense
————
Non-Operating Income (Expense)-42-38-123
Net Income Before Taxes-119-117-96-95
Income Taxes0001
Consolidated Net Income-118-117-96-96
Net Income From Continuing Operations-118-117-96-96
Net Income-118-117-96-96
EPS (Recurring)-1.42-1.37-1.53-1.94
EPS (Basic, Before Extraordinaries)-1.42-1.37-1.53-1.94
EPS (Diluted)-1.42-1.37-1.53-1.94
EBITDA-105-93-65-63
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio22.1014.08——
Gross Margin79.7276.7074.6066.67
Operating Margin-34.43-36.36-48.41-83.91
Net Margin-55.66-66.48-76.19-110.34
Shares Outstanding86856364
Market Capitalization4,6862,478——
Operating Lease Expense
————
Insider Trading Volume
$66.54$53.52$40.51$27.50$14.48● Close Price0.00M15.27M30.55M45.82M61.09MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Rogers CampbellChief Medical OfficerOct 22 '26Option Exercise6.5417,430114,02597,386Oct 26
Rogers CampbellChief Medical OfficerOct 22 '26Sale55.0123,9331,316,55473,453Oct 26
Farquhar John C.M.Chief Executive OfficerOct 12 '26Sale49.5738,9001,928,195283,014Oct 14
Rogers CampbellChief Medical OfficerSep 18 '26Option Exercise7.9413,179104,58899,638Sep 21
Rogers CampbellChief Medical OfficerSep 18 '26Sale50.1519,682987,05279,956Sep 21
Verghese VikramChief Financial OfficerSep 18 '26Sale50.7516,766850,926155,183Sep 18
Verghese VikramChief Financial OfficerSep 17 '26Sale50.117,579379,816171,949Sep 18
Verghese VikramChief Financial OfficerSep 15 '26Sale50.0166833,408179,528Sep 15
Verghese VikramChief Financial OfficerSep 14 '26Sale50.244,593230,744180,196Sep 15
Verghese VikramChief Financial OfficerSep 11 '26Sale50.0629,7141,487,459184,789Sep 15
Farquhar John C.M.Chief Executive OfficerSep 11 '26Sale50.003,890194,500321,914Sep 14
Farquhar John C.M.Chief Executive OfficerSep 10 '26Sale46.4235,0101,625,105325,804Sep 14
Verghese VikramChief Financial OfficerSep 08 '26Sale50.036,640332,212214,503Sep 10
Verghese VikramChief Financial OfficerSep 03 '26Sale49.6927,5401,368,471221,143Sep 04
Verghese VikramChief Financial OfficerSep 02 '26Sale50.605,876297,326248,683Sep 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.